Rephaeli A, Nordenberg J, Aviram A, Rabizadeh E, Zimra Y, Nudelman A, Novogrodsky A, Shaklai M
FELSENSTEIN MED RES CTR,IL-49100 TIKVA,ISRAEL. BAR ILAN UNIV,DEPT CHEM,IL-52900 RAMAT GAN,ISRAEL. HEMATOL INST,IL-49100 PETAH TIQWA,ISRAEL. TEL AVIV UNIV,BEILINSON MED CTR,ENDOCRINOL LAB,TEL AVIV,ISRAEL. TEL AVIV UNIV,SACKLER SCH MED,TEL AVIV,ISRAEL.
Int J Oncol. 1994 Jun;4(6):1387-91. doi: 10.3892/ijo.4.6.1387.
A study of the effects of three differentiating agents, butyric acid, retinoic acid and cytosine arabinoside on proliferation and differentiation of primary cultures, obtained from sixteen patients with myelo-proliferative disorder was conducted. The results showed that BA was an effective inhibitor of cell proliferation and inducer of cytodifferentiation. An acute non-lymphoblastic leukemia patient was treated with sodium butyrate. A temporary increase in differentiation-associated parameters were noted. However, the effects of SB were short-lived. The lack of clinical response led to the development of a BA prodrug pivaloyloxymethylbutyrate (AN-9). This prodrug was more potent in vitro than BA in the induction of cytodifferentiation and inhibition of cell proliferation.